Pomalidomide-C6-PEG1-C3-PEG1-butyl iodide is primarily used in the development of targeted cancer therapies. Its structure allows it to act as a linker in antibody-drug conjugates (ADCs), enabling the precise delivery of cytotoxic agents to cancer cells while minimizing damage to healthy tissues. This compound is particularly valuable in the treatment of hematological malignancies, such as multiple myeloma, where it enhances the efficacy of therapeutic agents by improving their solubility and stability. Additionally, its PEGylated components contribute to prolonged circulation in the bloodstream, increasing the therapeutic window and reducing dosing frequency. Researchers also utilize this compound in proteolysis-targeting chimeras (PROTACs) to degrade specific disease-causing proteins, offering a novel approach to drug development. Its versatility makes it a critical tool in advancing precision medicine and improving patient outcomes in oncology.